カテゴリ： GlobalData, アメリカ, 企業調査

VistaGen Therapeutics Inc (VTGN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：VistaGen Therapeutics Inc (VTGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3288
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：63
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
VistaGen Therapeutics Inc (VistaGen) is a biopharmaceutical company that develops new generation medicines for neuropsychiatric disorders. The company’s product includes AV-101, which is a oral antidepressant which is currently under clinical study in National Institute of Mental Health (NIMH). It conducts research on their human pluripotent stem cell platform to predict toxic chemicals in heart. The company conducts clinical trials of its product in treatment of chronic neuropathic pain, epilepsy, huntington’s disease and parkinson’s disease. It partners with other healthcare industries for researching and assessing the drug effects on cardiac risk. VistaGen is headquartered in South San Francisco, California, the US.

VistaGen Therapeutics Inc (VTGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VistaGen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
VistaGen Therapeutics and Baylor College of Medicine Enter into Agreement 12
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 13
VistaGen Therapeutics Enters Into Agreement With Celsis In Vitro Technologies 14
VistaGen Therapeutics Enters Into Research Agreement With Duke University 15
Licensing Agreements 16
BlueRock Therapeutics Enters into Licensing Agreement with VistaGen Therapeutics 16
VistaGen Therapeutics Enters into Licensing Agreement with University Health Network 17
VistaGen Therapeutics Enters Licensing Agreement with University Health Network 18
VistaGen Therapeutics Enters Into Licensing Agreement With McEwen Centre for Regenerative Medicine 19
Equity Offering 20
VistaGen Therapeutics Raises USD15 Million in Public Offering of Shares and Warrants 20
Vistagen Therapeutics Raises USD2.4 Million in Public Offering of Shares and Warrants 22
VistaGen Therapeutics Raises USD1 Million in Private Placement of Shares 24
VistaGen Therapeutics Raises USD1 Million in Private Placement 25
VistaGen Therapeutics Raises USD10 Million in Public Offering of Shares and Warrants 26
VistaGen Therapeutics Raises USD1.6 Million in Private Placement of Securities 28
VistaGen Therapeutics Completes First Tranche Of Private Placement Of Shares For US$0.025 Million 29
Debt Offering 30
VistaGen Therapeutics Raises USD3 Million in Private Placement of 10% Notes 30
VistaGen Therapeutics Raises USD1 Million in Private Placement of 10% Notes 31
VistaGen Therapeutics Inc – Key Competitors 32
VistaGen Therapeutics Inc – Key Employees 33
VistaGen Therapeutics Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 14, 2018: VistaGen Therapeutics announces fiscal 2019 first quarter financial results 35
Jun 26, 2018: VistaGen Therapeutics Announces Fiscal Year 2018 Financial Results 37
Feb 12, 2018: VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results 39
Nov 09, 2017: VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update 40
Aug 14, 2017: VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update 42
Jun 29, 2017: VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update 44
Feb 13, 2017: VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 46
Corporate Communications 48
Aug 21, 2017: VistaGen Therapeutics Expands VistaStem’s Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD 48
Product News 49
07/10/2017: VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain 49
04/27/2017: VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101′s Potential for Treating Neuropathic Pain 50
Product Approvals 52
Jan 03, 2018: VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder 52
Clinical Trials 53
Jun 13, 2018: VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101 53
Apr 05, 2018: VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder 54
Mar 19, 2018: VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 55
Jan 29, 2018: VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder 56
Jan 22, 2018: VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets Investor Conference 58
Oct 26, 2017: VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder 59
Jun 22, 2017: VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101′s Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain 60
Jan 05, 2017: VistaGen Therapeutics to Present at Biotech Showcase 2017 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VistaGen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
VistaGen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VistaGen Therapeutics and Baylor College of Medicine Enter into Agreement 12
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 13
VistaGen Therapeutics Enters Into Agreement With Celsis In Vitro Technologies 14
VistaGen Therapeutics Enters Into Research Agreement With Duke University 15
BlueRock Therapeutics Enters into Licensing Agreement with VistaGen Therapeutics 16
VistaGen Therapeutics Enters into Licensing Agreement with University Health Network 17
VistaGen Therapeutics Enters Licensing Agreement with University Health Network 18
VistaGen Therapeutics Enters Into Licensing Agreement With McEwen Centre for Regenerative Medicine 19
VistaGen Therapeutics Raises USD15 Million in Public Offering of Shares and Warrants 20
Vistagen Therapeutics Raises USD2.4 Million in Public Offering of Shares and Warrants 22
VistaGen Therapeutics Raises USD1 Million in Private Placement of Shares 24
VistaGen Therapeutics Raises USD1 Million in Private Placement 25
VistaGen Therapeutics Raises USD10 Million in Public Offering of Shares and Warrants 26
VistaGen Therapeutics Raises USD1.6 Million in Private Placement of Securities 28
VistaGen Therapeutics Completes First Tranche Of Private Placement Of Shares For US$0.025 Million 29
VistaGen Therapeutics Raises USD3 Million in Private Placement of 10% Notes 30
VistaGen Therapeutics Raises USD1 Million in Private Placement of 10% Notes 31
VistaGen Therapeutics Inc, Key Competitors 32
VistaGen Therapeutics Inc, Key Employees 33
VistaGen Therapeutics Inc, Subsidiaries 34

List of Figures
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VistaGen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VistaGen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[VistaGen Therapeutics Inc (VTGN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • CellSeed Inc (7776)：企業の製品パイプライン分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • Infant Bacterial Therapeutics AB (IBT B)-製薬・医療分野：企業M&A・提携分析
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops prophylactic therapies for the medical needs of the premature infant. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal i …
  • E-CO Energi Holding AS：企業の戦略的SWOT分析
    E-CO Energi Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Elong Inc：企業の戦略・SWOT・財務分析
    Elong Inc - Strategy, SWOT and Corporate Finance Report Summary Elong Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Shinva Medical Instrument Co Ltd (600587)：企業の財務・戦略的SWOT分析
    Shinva Medical Instrument Co Ltd (600587) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • I-O Data Device, Inc. (6916)：企業の財務・戦略的SWOT分析
    I-O Data Device, Inc. (6916) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Occidental Petroleum Corporation (OXY)-エネルギー分野：企業M&A・提携分析
    Summary Occidental Petroleum Corporation (Occidental) is an oil and gas exploration and production company with integrated assets. The company is active in upstream exploration and production; midstream and marketing; and chemicals business. The oil and gas business explores for, develops and produc …
  • UGI Corp (UGI)：石油・ガス：M&Aディール及び事業提携情報
    Summary UGI Corp (UGI) is a holding company providing energy products and services. Through subsidiaries, the company stores, transports, distributes and markets energy products and related services. It distributes propane and butane both domestically and internationally and provides natural gas and …
  • Raschig GmbH：企業の戦略的SWOT分析
    Raschig GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Horama SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Horama SA (Horama) is a biotechnology company, which develops gene therapy products based on recombinant adeno-associated virus (rAAV) vectors for the treatment of rare ophthalmic diseases, including retinopathies and maculopathies. Its pipeline gene replacement products include HORA-RPE65, …
  • Amazon.com, Inc.：企業のM&A・事業提携・投資動向
    Amazon.com, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Amazon.com, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Baloise Belgium NV：企業の戦略・SWOT・財務分析
    Baloise Belgium NV - Strategy, SWOT and Corporate Finance Report Summary Baloise Belgium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Donaldson Co Inc (DCI)：企業の財務・戦略的SWOT分析
    Donaldson Co Inc (DCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Bangkok Chain Hospital Public Co Ltd (BCH)：企業の財務・戦略的SWOT分析
    Bangkok Chain Hospital Public Co Ltd (BCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Orthosera GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary Orthosera GmbH (OrthoSera), formerly Lacerta Technologies GmbH is a regenerative medicine company that develops blood serum for human diseases. The company offers Albumin, a bone protein used in treatment of patients suffering from bone loss. It develops technologies for identification of ne …
  • Curetis NV (CURE)：企業の製品パイプライン分析2018
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Dufry AG (DUFN)：企業の財務・戦略的SWOT分析
    Dufry AG (DUFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Tompkins Financial Corp (TMP)
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Mylan NV (MYL)-製薬・医療分野：企業M&A・提携分析
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, ca …
  • Dairygold Co-operative Society Ltd：企業の戦略的SWOT分析
    Dairygold Co-operative Society Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆